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Purpose: The underlying cause of myasthenia gravis (MG) is unknown, although it 
likely involves a genetic component. However, no common genetic variants have 
been unequivocally linked to autoimmune MG. We sought to identify the genetic 
variants associated with an increased or decreased risk of developing MG in sam-
ples from a Korean Multicenter MG Cohort. Materials and Methods: To deter-
mine new genetic targets related to autoimmune MG, a whole genome-based single 
nucleotide polymorphisms (SNP) analysis was conducted using an AxiomTM Ge-
nome-Wide ASI 1 Array, comprising 598375 SNPs and samples from 109 MG pa-
tients and 150 neurologically normal controls. Results: In total, 641 SNPs from 
five case-control associations showed p-values of less than 10-5. From regional 
analysis, we selected seven candidate genes (RYR3, CACNA1S, SLAMF1, SOX5, 
FHOD3, GABRB1, and SACS) for further analysis. Conclusion: The present study 
suggests that a few genetic polymorphisms, such as in RYR3, CACNA1S, and 
SLAMF1, might be related to autoimmune MG. Our findings also encourage fur-
ther studies, particularly confirmatory studies with larger samples, to validate and 
analyze the association between these SNPs and autoimmune MG.
Key Words:   Myasthenia gravis, whole genome-based SNP analysis, RYR3, CAC-
NA1S, SLAMF1
INTRODUCTION
 
Myasthenia gravis (MG) is a defect of nerve-muscle transmission caused by auto-
antibodies to different components of the postsynaptic membrane.1 Similar to oth-
er autoimmune diseases, tolerance breakdown is a highly complex and multifacto-
rial process, resulting from the alteration of multiple pathways. As previously 
demonstrated in other autoimmune diseases,2 genetic factors are thought to play an 
important role in the pathogenesis of MG, despite its limited heritability. MG pa-
tients, as well as their close relatives, are often affected by other autoimmune dis-
eases,3 which strongly suggests shared genetic mechanisms.
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muscle involvement. Patients were classified as having a 
generalized disease if there was any weakness on exertion 
of the facial (except the orbicularis oculi), oropharyngeal, 
neck, respiratory, axial, or limb muscles, which could be 
identified either subjectively or during neurological exami-
nation. Ocular MG was defined as follows: ocular distur-
bances are the first and sole manifestation of MG and no 
progression to generalized MG within the first 3 years has 
been recorded. Acetylcholine receptor (AChR) binding an-
tibodies determined by radioimmunoassay were considered 
positive at ≥0.5 nmol/L and AChR blocking antibodies de-
termined by radioreceptor assay were considered positive 
≥31% blocking. We excluded MG patients with autoim-
mune diseases other than MG.
The genotype data of normal controls were obtained from 
the samples of another study, which involved mutually unre-
lated Korean individuals within the Republic of Korea. All 
participants underwent a detailed medical history interview. 
None had history of MG, amyotrophic lateral sclerosis 
(ALS), Alzheimer’s disease, ataxia, autism, bipolar disorder, 
dementia, dystonia, or Parkinson’s disease. All participants 
were interviewed for family history in detail. None had any 
first-degree relative with a known primary neurological dis-
order, including MG, ALS, ataxia, autism, dystonia, Parkin-
son’s disease, or schizophrenia. The control and the case co-
horts were drawn from the same ethnic origin and were not 
matched by age or sex with the MG samples. The control 
cohort consisted of 33 men and 117 women.
The ages of the patients at onset of the disease ranged 
from 12 to 62 years of age (mean=43.6 years). The disease 
onset was defined as the time when weakness was first not-
ed. The MG patients were classified by disease type (ocular 
or generalized), the presence or absence of thymic hyperpla-
sia/thymoma as determined by a thymic pathology study, 
and whether anti-AChR blocking or binding antibody was 
positive or negative.
After obtaining consent, each participant provided a ve-
nous blood sample that was collected in ethylene diamine tet-
raacetic acid-coated tubes. All samples were labeled with an 
anonymous code number linked only to demographic and 
clinical information. 
Genotyping and quality control
The patients’ genomic DNA was extracted from peripheral 
blood using a standard protocol. We genotyped 598375 
SNPs from 109 MG patients using an AxiomTM Genome-
Wide ASI 1 Array Chip (Affymetrix, Santa Clara, CA, USA), 
Among the genetic factors investigated in MG, major histo-
compatibility complex holds a unique place. It has been re-
producibly associated with MG in many different populations 
and it shows large effects. However, which genes are respon-
sible for the association of this large and essential region is not 
yet known. Various genes associated with MG have been 
identified, including cholinergic receptor nicotinic alpha 1 
(CHRNA1),4,5 protein tyrosine phosphatase, non-receptor type 
22 (PTPN22),6,7 and cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA4).8,9 Despite demonstrating associations among 
many genes and MG,10 their roles in MG remain elusive and 
precise identification thereof at the molecular level remains 
challenging. Identification of specific genetic variants associ-
ated with autoimmune MG will improve our understanding of 
fundamental disease mechanisms.
To identify genetic factors that might be relevant in the 
pathogenesis of autoimmune MG, we genotyped 598375 
unique single nucleotide polymorphisms (SNPs) across the 
genome using an AxiomTM Genome-Wide ASI 1 Array Chip 
(Affymetrix, Santa Clara, CA, USA) in 109 patients with 
autoimmune MG and 150 neurologically normal controls.
MATERIALS AND METHODS
　　　
Participants
Samples were obtained from four university hospitals 
(Konyang University Hospital, Gangnam Severance Hospi-
tal, Chugnam National University Hospital, and Pusan Na-
tional University Hospital). All were mutually unrelated 
Korean subjects and provided written informed consent to 
participate in the study, as stipulated by the respective Insti-
tutional Review Boards. Additionally, the study was per-
formed according to the Declaration of Helsinki.
DNA from 109 unique and mutually unrelated Korean in-
dividuals diagnosed with autoimmune MG was selected for 
the analysis. Their diagnoses were based on clinical signs of 
fluctuating weakness of voluntary muscles with fatigability 
and either a positive response to neostigmine or electrophys-
iological evidence of a greater than 10% decrease in the 
negative-peak amplitude of compound muscle action poten-
tial upon supramaximal repetitive (2 or 3 Hz) nerve stimula-
tion. A positive response to the neostigmine test was defined 
as follows: muscle weakness caused by MG is temporarily 
reversed following the administration of neostigmine. 
Eligible patients were classified as having ocular MG or 
generalized MG according to the clinical distribution of 
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tients. As the sample size was relatively small in our study, 
multiple hit SNPs from all association tests had more power 
than a single association test. For each SNP, we computed a 
series of summary statistics and association tests using the 
PLINK toolset. Five association tests were computed: a two 
degrees of freedom genotypic test in 2×3 tables, a dominant 
model, an additive model (Cochran-Armitage trend test), a 
recessive model, and the basic allelic test. Odds ratios, as 
well as upper and lower bound 95% CIs, were computed for 
each SNP’s minor allele.
RESULTS
 
In total, 109 autoimmune MG patients with complete geno-
typic and phenotypic data were enrolled in this study. All 
were used for the subsequent association analyses. The 
baseline characteristics of the 109 patients are summarized 
in Table 1. At the time of diagnosis, their ages in years were 
47.2±15.8 and their mean disease duration was 4.2 years. 
Overall, 68 patients (62%) were women. Among 109 cases, 
50 (46%) presented with generalized symptoms, 53 (49%) 
had a purely ocular manifestation, and the remaining six 
could not be classified due to uncertain clinical information. 
Of the 91cases in which the AChR antibody test was per-
formed, 55 cases (60%) were positive. Of the 31 cases in 
which the thymic pathology study was performed, 18 cases 
(58%) had thymic hyperplasia/thymoma. Genome-wide as-
sociation (GWA) analyses were performed after the quality 
control (QC) procedure to test the association with MG. In 
according to the manufacturer’s instructions. Data from 150 
control samples were obtained from another study and were 
assayed with an AxiomTM Genome-Wide ASI 1 Array Chip. 
The Axiom ASI Chip provides 88% common variant cover-
age in Asians and can provide 74% rare variant [minor allele 
frequency (MAF) ≤5%] coverage in Asians. 
To reduce potential concerns for batch effects and the 
possibility of false associations, we applied highly stringent 
quality control measures to select SNPs for use in the case-
control datasets. The quality control procedures were per-
formed on each of the 598K SNPs before the association 
tests were conducted. The SNP set was filtered based on the 
genotype call rates (≥90%) and MAF (≥0.01). Hardy-Wein-
berg equilibrium (HWE) was calculated for individual SNPs 
using an exact test. All of the SNPs reported in this manu-
script demonstrated HWE p values >10-4. After filtering, 
502500 polymorphic SNPs were analyzed on chromosome 
1 through chromosome 22 and 13850 and 13835 SNPs for 
chromosome X and Y, respectively. The average call rate 
for the filtered SNPs was 99.3%. We removed the patients 
if their percentage of missing genotypes was more than 5% 
or if there was evidence of possible contamination in their 
DNA samples.
Statistical analysis
We evaluated associations between SNP markers and auto-
immune MG. First, we performed the association tests on all 
MG patients and control subjects, as well as undertook fur-
ther analysis of samples from subgroups such as AChR-pos-
itive, AChR-negative, ocular MG, and generalized MG pa-
Table 1. Characteristics of the Study Population
Patients Controls
Number of population 109 150
Gender, n (%)
    Male 41 (38)   33 (22)
    Female 68 (62) 117 (78)
Age (mean±SD, yrs) 47.2±15.8 (range: 15-80) -
Mean duration of disease (yrs) 4.2 -
AChR antibody positivity, n (%) 55/91 (60)† -
Thymus pathology, n (%) 18/31 (58)‡ -
    Thymus hyperplasia   9 (29)
    Thymoma   9 (29)
Distribution of weakness, n (%)*
    Ocular 53 (49) -
    Generalized 50 (46) -
SD, standard deviation; AChR, acetylcholine receptor.
*Information of 6 samples is uncertain.
†91 cases are performed the AChR antibody test.
‡31 cases are performed the thymic pathology study.
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ysis also was performed in this manner. Those passing the 
QC test included 515340 SNPs (86.1%) in the AChR-posi-
tive MG and control association test, 519823 SNPs (86.9%) 
in the AChR antibody-negative MG and control association 
test, 515032 SNPs (86.1%) in the ocular MG and control 
association test, and 515615 SNPs (86.2%) in the general-
ized MG and control association test. A summary of the 
quality control statistics of genome-wide data is presented 
in Table 2.
The sample size of the total MG data set was too small to 
select a candidate SNP for MG. Thus, we repeated the sta-
tistical analysis for four subgroups of patients with general-
the sample QC, all 109 samples from the MG cohort passed 
the genotype quality threshold and were included in the fi-
nal analysis. 
The quality control criteria for SNP selection were 1) mi-
nor allele frequency >0.01, 2) p>10-4 in the Hardy-Weinberg 
Equilibrium test, and 3) Cluster QC >10-4. Of the 598375 
SNPs studied, 516335 SNPs passed the QC (representing 
86.3% of all SNPs assayed) in the MG and control associa-
tion test. A quantile-quantile plot for the genome-wide phase, 
in which the observed -log10 p-values were plotted against 
the expectation under the null hypothesis, showed an ex-
cess of significant associations. The QC for subgroup anal-
Table 3. Top 20 p-value Lists for Total MG and Controls Association Study
rs_number p value Model Chr Position Region Gene MAF_CASE MAF_CTRL
rs7141349 8.2380E-07 Allele 14 47466935 0.55 0.33
rs7154708 1.7520E-06 Codominant 14 47462218 0.55 0.34
rs1258099 2.5279E-06 Dominant   9 77805019 Intron PCSK5 0.25 0.43
rs11842715 3.0170E-06 Dominant 13 27315033 0.02 0.13
rs12486119 4.7299E-06 Dominant   3 30869474 Intron GADL1 0.28 0.44
rs2683954 4.9140E-06 Codominant 14 47455102 0.57 0.37
rs10234656 5.7640E-06
Dominant,  
  codominant
  7 40929185 0.08 0.01
rs1952442 1.0462E-05 Recessive 14 47426380 0.50 0.32
rs883159 1.1099E-05 Recessive 14 47428814 0.50 0.32
rs1012947 1.1624E-05 Dominant 21 25788683 0.26 0.13
rs11899394 1.1653E-05 Dominant   2 45784660 Intron PRKCE 0.06 0.19
rs1500722 1.1904E-05 Allele 14 32809609 Intron NPAS3 0.29 0.13
rs16897888 1.3136E-05 Dominant   6 30848494 0.06 0.19
rs10858625 1.6307E-05 Dominant 12 86517374 0.20 0.37
rs2829753 1.6603E-05 Dominant 21 25752161 0.24 0.11
rs2770316 1.6805E-05 Allele   6 70226612 0.64 0.45
rs12659838 1.6935E-05 Codominant   5 22330751 Intron CDH12 0.35 0.18
rs2208953 1.7123E-05 Allele 10 10840508 0.62 0.43
rs17166605 1.8843E-05 Dominant   7 13030286 0.60 0.41
rs7177307 1.9309E-05 Allele 15 44943871 0.29 0.14
MG, myasthenia gravis; Chr, chromosome; MAF, minor allele frequency; CTRL, control.
Table 2. Summary Statistics for Quality Control on Genome-Wide Data
Study
Pre QC Filters Post QC
SNPs Samples
Samples 
call rate 
<95%
Failed
gender
check
SNPs
MAF
<1%
HWE
p<1.0×10-4 
(CTL)
SNPs 
call rate 
<95%
Cases Controls SNPs
MG & CTRL 598375 259 0 0 77711 454 3875 109 150 516335
Subgroup analysis
    AChR-positive 598375 186 0 0 78235 454 4346   36 150 515340
    AChR-negative 598375 205 0 0 75345 454 2753   55 150 519823
    Ocular 598375 205 0 0 75345 454 2753   55 150 519823
    Generalized 598375 203 0 0 79245 454 3644   53 150 515032
SNP, single nucleotide polymorphisms; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; MG, myasthenia gravis; AChR, acetylcholine re-
ceptor; QC, quality control; CTRL, control.
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Table 4. Top 20 p-value Lists for AChR Antibody-Positive MG and Controls Association Study
rs_number p value Model Chr Position Region Gene MAF_CASE MAF_CTRL
rs3018886 8.3148E-08 Recessive   8 95128859 0.71 0.46
rs7141349 2.0482E-06 Recessive 14 47466935 0.57 0.33
rs16832753 2.5172E-06 Recessive   3 183110681 0.30 0.13
rs7154708 3.7508E-06 Codominant 14 47462218 0.59 0.34
rs12550945 3.9981E-06
Dominant,  
  codominant
  9 80374542 0.08 0.00
rs10487449 5.4366E-06 Recessive   7 125859302 0.38 0.23
rs6558758 6.0900E-06 Dominant   8 3140536 Intron CSMD1 0.18 0.05
rs4588819 7.1397E-06 Recessive   8 95137400 0.55 0.39
rs11817310 7.4844E-06 Allele 10 42603032 Intron BMS1 0.14 0.02
rs6455327 7.5314E-06 Recessive   6 70319290 0.63 0.39
rs2453911 7.7731E-06 Dominant   9 75355673 0.35 0.17
rs2683954 8.0170E-06 Recessive 14 47455102 0.58 0.37
rs367964 8.2153E-06 Dominant   9 75353819 0.36 0.17
rs6114735 9.0742E-06 Recessive 20 24393155 0.54 0.34
rs3753381 9.6391E-06 Allele   1 158866034 Intron SLAMF1 0.25 0.09
rs756969 1.0419E-05 Recessive   7 125838952 0.38 0.23
rs3018899 1.0566E-05 Recessive   8 95143771 0.62 0.42
rs10496615 1.0982E-05 Recessive   2 123995938 0.60 0.39
rs156085 1.1260E-05
Dominant, 
  codominant
  5 139522621 0.06 0.00
rs2770316 1.1267E-05 Allele   6 70226612 0.69 0.45
AChR, acetylcholine receptor; MG, myasthenia gravis; Chr, chromosome; MAF, minor allele frequency; CTRL, control.
Table 5. Top 20 p-value Lists for AChR Antibody-Negative MG and Controls Association Study
rs_number p value Model Chr Position Region Gene MAF_CASE MAF_CTRL
rs956412 1.6485E-08 Allele   4 47052607 Intron GABRB1 0.15 0.01
rs17571554 6.7382E-08
Dominant, 
  codominant
  4 47056014 Intron GABRB1 0.11 0.00
rs6855913 6.8790E-08 Allele   4 47054238 Intron GABRB1 0.15 0.01
rs7664341 8.6776E-08 Allele   4 47056204 Intron GABRB1 0.15 0.01
rs12150099 4.1861E-07 Allele 17 49939613 0.22 0.04
rs2676631 5.6777E-07
Dominant, 
  codominant
  8 69487885 0.17 0.02
rs11983497 6.4676E-07 Recessive   7 13387160 0.35 0.21
rs9856502 7.4457E-07 Recessive   3 81539342 0.54 0.36
rs1258099 8.7326E-07 Dominant   9 77805019 Intron PCSK5 0.17 0.43
rs7825012 1.5895E-06 Recessive   8 9709295 0.56 0.36
rs4239186 2.0523E-06 Allele 17 49932218 0.22 0.05
rs3862683 2.5963E-06 Recessive 18 48189303 Intron DCC 0.68 0.45
rs16842229 3.5855E-06
Dominant, 
  codominant
  1 222038015 Intron TP53BP2 0.07 0.00
rs13392766 4.0898E-06 Recessive   2 80002716 Intron CTNNA2 0.42 0.23
rs17341778 4.2374E-06 Recessive   7 71027289 Intron CALN1 0.28 0.14
rs7680490 4.3651E-06 Recessive   4 107596146 0.57 0.34
rs9827643 4.4527E-06 Recessive   3 60188341 0.40 0.27
rs8068809 4.5573E-06 Recessive 17 67931624 0.29 0.13
rs773478 5.1914E-06
Dominant, 
  codominant
12 75838122 0.14 0.02
rs773461 5.6886E-06
Dominant, 
  codominant
12 75831749 0.14 0.02
AChR, acetylcholine receptor; MG, myasthenia gravis; Chr, chromosome; MAF, minor allele frequency; CTRL, control.
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selected from the analysis between generalized MG cases 
and controls.
DISCUSSION
In this study, we generated genome-wide SNP data consist-
ing of more than 500K genotypes from multicenter cohort 
patients with autoimmune MG and controls derived from 
the samples used in another study. The use of tagging SNPs 
greatly improves the power of association studies, as the 
same information from a larger number of SNPs can be gath-
ered by genotyping only one subset of loci. The Axiom ASI 
Array provides 88% common variant coverage in Asians. 
Furthermore, it can provide 74% rare variant (MAF ≤5%) 
coverage in Asians. Tagged SNPs on the Axiom Genome-
Wide ASI Array plate were selected from --515K HapMap 
markers, --72K 1000 Genome project markers, and --10K 
other source markers, including --2K indels. Thus, most 
known genetic variations identified by the HapMap consor-
ized MG (n=50), ocular MG (n=53), AChR antibody posi-
tive MG (n=55), and AChR antibody negative MG (n=36). 
In every case, the subgroup was compared with the full 
control cohort (n=150). Of these, 641 SNPs showed signifi-
cant association in all case-control association tests based 
on the pre-set level of significance (p-values less than 10-5); 
the top 20 p-values of SNPs are shown in Table 3-7. 
From these results, we selected candidate association 
regions in two different ways. First, we selected common 
hit regions from all association datasets. Second, we per-
formed a regional analysis on each case-control association 
dataset, as significant peaks usually tend to occur near each 
other. Finally, we selected seven genes (RYR3, CACNA1S, 
SLAMF1, SOX5, FHOD3, GABRB1, and SACS) for further 
analysis.
The SLAMF1, CACNA1S, and RYR3 genes were selected 
from the analysis between the AChR antibody positive MG 
cases and controls. The GABRB1 and SACS genes were se-
lected from the analysis between AChR antibody negative 
MG cases and controls. The SOX and FHOD3 genes were 
Table 6. Top 20 p-value Lists for Ocular MG and Controls Association Study
rs_number p value Model Chr Position Region Gene MAF_CASE MAF_CTRL
rs10234656 7.9221E-09
Dominant, 
  codominant
  7 40929185 0.13 0.01
rs28573248 8.3541E-07
Dominant,    
  codominant
  7 40973171 0.13 0.02
rs1460281 1.0655E-06 Dominant 18 71620567 0.16 0.39
rs12486119 2.5028E-06 Dominant   3 30869474 Intron GADL1 0.23 0.44
rs12581407 3.0422E-06 Allele 12 127346421 0.37 0.15
rs3823793 3.7607E-06
Dominant, 
  codominant
  7 77578104 Intron MAGI2 0.09 0.01
rs2908967 3.8309E-06
Dominant, 
  codominant
17 11357947 Intron FLJ45455 0.10 0.01
rs3742888 4.0026E-06 Allele 14 68440958 Intron ACTN1 0.20 0.05
rs2908968 4.1762E-06
Dominant, 
  codominant
17 11357413 Intron FLJ45455 0.10 0.01
rs2965404 4.2462E-06 Codominant   7 21716027 Intron DNAH11 0.39 0.18
rs1366302 4.4270E-06 Recessive   3 161143969 0.39 0.28
rs10261234 5.3672E-06 Allele   7 12063192 0.06 0.27
rs1603257 6.2248E-06 Recessive   3 76331396 0.27 0.18
rs1938791 6.4977E-06 Recessive 11 58502814 0.54 0.34
rs17788458 6.6730E-06 Recessive   3 76338564 0.28 0.18
rs9533748 7.5909E-06 Dominant 13 31642594 Intron FRY 0.21 0.41
rs6664468 7.9323E-06 Allele   1 224238098 3’UTR C1orf55 0.40 0.18
rs3131888 8.1942E-06 Dominant   6 29771868 0.23 0.45
rs7625918 1.0055E-05 Allele   3 196156271 0.30 0.12
rs12023502 1.1876E-05 Allele   1 215423103 0.42 0.21
MG, myasthenia gravis; Chr, chromosome; MAF, minor allele frequency; UTR, untranslated region; CTRL, control.
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p-value of less than 0.05. Based on this threshold, only one 
SNP (rs10234656, p-value=7.9×10-9 in the subgroup analy-
sis for ocular MG) was significant after the correction. 
However, this SNP showed the highest p-value within only 
a single region, and we did not focus on further analysis be-
cause significant peaks usually tend to occur near each oth-
er in genome-wide association study (GWAS) data. Ex-
cluding this one SNP, none of the other SNPs listed were 
significant after the correction. This suggests that the MG 
phenotype is not driven by a single powerful locus. 
However, other possible explanations exist as to why our 
study might not have detected an SNP that convincingly re-
lates to disease risk. Firstly, the Bonferroni correction is 
known to be too conservative, especially in whole-genome 
association studies where dependence (i.e., linkage disequi-
librium) among SNPs is ignored.11 Second, the power of our 
study was limited by its sample size and the lack of age-
matched and sex-matched controls. Finally, it is possible 
that autoimmune MG consists of a diverse group of clinical-
ly indistinguishable disorders, each driven by different loci. 
Such disease and locus heterogeneity would interfere with 
tium were assessed in this project. Furthermore, the SNPs 
on the Axiom ASI SNP Chip comprise a large representa-
tion of functionally relevant markers, making the assay ide-
ally suited for assessing whole-genome associations. 
Our data provided a power of 80% to detect an allelic as-
sociation with an odds ratio of more than 2.75 and less than 
0.33 at an asymptotic p-value of 0.000001. This calculation 
was based on the average observed MAF of 23.7% and as-
sumed either that the causal variant is typed or that there is 
complete and efficient tagging of common variation by the 
genotyped SNPs. The limited power of our study was a 
consequence of the small sample size, though the digital 
nature of the data allows it to be supplemented with geno-
type information from additional sample series, thereby in-
creasing the power over time. 
Analysis of our data revealed 641 SNPs with a p-value 
less than 0.00001 and with odds ratios ranging from 0.5 
(95% CI 0.4-0.7) to 2.1 (95% CI 1.5-3.0). A Bonferroni 
correction based on the 502500 independent tests used for 
analysis indicated that a pre-correction p-value of less than 
9.9×10-8 would be needed to provide a corrected significant 
Table 7. Top 20 p-value Lists for Generalized MG and Controls Association Study
rs_number p value Model Chr Position Region Gene MAF_CASE MAF_CTRL
rs16832753 2.8384E-08 Recessive   3 183110681 0.34 0.13
rs3130118 7.8913E-07 Codominant   6 30473719 0.45 0.20
rs12539444 1.0970E-06 Recessive   7 7156698 0.62 0.38
rs10262834 2.0167E-06 Allele   7 110091762 Intron IMMP2L 0.10 0.01
rs488173 2.1923E-06 Recessive 18 32156598 Intron FHOD3 0.49 0.26
rs1258099 3.1808E-06 Dominant   9 77805019 Intron PCSK5 0.19 0.43
rs6747418 3.7847E-06 Recessive   2 179591996 0.31 0.19
rs35861024 4.2679E-06
Dominant, 
  codominant
11 35148413 Intron CD44 0.17 0.04
rs3804925 4.5803E-06
Dominant, 
  codominant
  3 7555979 Intron GRM7 0.13 0.02
rs17169097 5.4048E-06 Dominant   7 15846487 0.36 0.17
rs6114735 6.1284E-06 Recessive 20 24393155 0.55 0.34
rs11135369 6.2397E-06
Dominant, 
  codominant
  5 155219422 0.08 0.00
rs277203 6.2397E-06
Dominant, 
  codominant
12 42320426 0.08 0.00
rs7177307 6.2397E-06 Recessive 15 44943871 0.29 0.14
rs2242290 6.4055E-06 Codominant   2 102951854 0.36 0.15
rs7141349 6.8138E-06 Recessive 14 47466935 0.57 0.33
rs11593843 7.3374E-06
Dominant, 
  codominant
10 55490462 Intron PCDH15 0.11 0.01
rs2507976 7.8462E-06 Dominant   6 31459866 0.18 0.37
rs359371 7.9849E-06 Recessive 13 64090969 0.41 0.24
rs1611985 8.6476E-06 Recessive 12 11564413 0.66 0.44
MG, myasthenia gravis; Chr, chromosome; MAF, minor allele frequency; CTRL, control.
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erated in whole-genome association studies should be inter-
preted cautiously because of the inevitably high false-positive 
rate that occurs whenever several hundred thousand tests are 
undertaken on the same dataset. For example, Maraganore, 
et al.20 identified 13 putative SNPs that seemed to be associ-
ated with Parkinson’s disease, but none have been confirmed 
in subsequent independent studies.21-25
To address the concern regarding false positive associa-
tions, it is our intention to replicate our current study using 
the same Axiom Genome-Wide ASI 1 Array in an additional 
sample set of equal or greater size drawn from the Korean 
population. Joint analysis of these data sets will significantly 
increase our power to detect an allelic association, and loci 
that are common to both Korean and other Asian popula-
tions will be further analyzed to determine the precise genet-
ic variation that conveys increased susceptibility to autoim-
mune MG.
In summary, we report data from a whole-genome associ-
ation study of a large group of autoimmune MG patients 
and neurologically normal control samples. In total, 641 loci 
showing potentially significant associations with MG were 
identified with a genotypic p-value of less than 0.00001. To 
overcome the possibility of false-positive findings, this study 
will be replicated in a separate cohort of 120 Korean MG 
cases-control pairs. From regional analysis, we selected 
seven genes (RYR3, CACNA1S, SLAMF1, SOX5, FHOD3, 
GABRB1, and SACS) for further analyses. Among the sev-
en genes, we suggest that three genes (RYR3, CACNA1S, 
and SLAMF1) are associated with autoimmune MG. How-
ever, speculating on the plausibility and the biological sig-
nificance of these candidate loci is premature, as additional 
genetic data are needed to confirm the notion that the E-C 
coupling gene or SLAMF1 gene are associated with auto-
immune MG.
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